2型糖尿病患者的心血管与肾脏风险:以过度脂肪堆积为重点的当代认识
在高收入国家,2型糖尿病的动脉粥样硬化并发症因传统危险因素管理和吸烟减少而显著下降,但过度脂肪堆积是心力衰竭和慢性肾脏病的重要驱动因素,且肥胖水平基本未变,心力衰竭风险下降较少甚至可能上升。作者基于多来源证据阐述过度脂肪堆积在糖尿病发生前即影响多数风险,并探讨减重及钠-葡萄糖协同转运蛋白2抑制剂可能通过相关通路产生心肾获益。
要点
- 高收入国家2型糖尿病动脉粥样硬化并发症因血脂、血压、血糖管理和吸烟减少而显著下降。
- 过度脂肪堆积是心力衰竭和慢性肾脏病的更强驱动因素,肥胖水平基本未变使心力衰竭风险下降较少或上升。
- 作者认为钠-葡萄糖协同转运蛋白2抑制剂的心肾获益可能部分来自干扰过度脂肪堆积相关通路。
核心结论
- 过度脂肪堆积必须在糖尿病发生前很久就影响多数风险,尤其在年轻发病的2型糖尿病中更为突出。
- 所有观察提示需要在2型糖尿病中更早处理过度脂肪堆积。
研究设计与样本
- 基于多来源证据的综述,未报告系统检索范围。
主要发现
- 高收入国家2型糖尿病的动脉粥样硬化并发症率随时间显著下降,归因于血脂、血压、血糖水平等传统危险因素管理改善和人群吸烟减少。
- 过度脂肪堆积是心力衰竭更强的驱动因素,肥胖水平基本未变,心力衰竭风险下降较少,且在年轻发病的2型糖尿病增加人群中可能上升。
- 过度体重也是慢性肾脏病被低估的危险因素。
- 作者推测血流动力学、细胞营养过剩和炎症等通路可被通过生活方式或药物的有意减重所有利影响。
- 作者认为钠-葡萄糖协同转运蛋白2抑制剂的心肾结局获益可能部分来自干扰这些相同通路。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In high-income countries, rates of atherosclerotic complications in type 2 diabetes have declined markedly over time due to better management of traditional risk factors including lipids, blood pressure, and glycemia levels. Population-wide reductions in smoking have also helped lower atherosclerotic complications and so reduce premature mortality in type 2 diabetes. However, as excess adiposity is a stronger driver for heart failure (HF), and obesity levels have remained largely unchanged, HF risks have not declined as much and may even be rising in the increasing number of people developing type 2 diabetes at younger ages. Excess weight is also an underrecognized risk factor for chronic kidney disease (CKD). Based on evidence from a range of sources, we explain how excess adiposity must be influencing most risks well before diabetes develops, particularly in younger-onset diabetes, which is linked to greater excess adiposity. We also review potential mechanisms linking excess adiposity to HF and CKD and speculate on how some of the responsible pathways-e.g., hemodynamic, cellular overnutrition, and inflammatory-could be favorably influenced by intentional weight loss (via lifestyle or drugs). On the basis of available evidence, we suggest that the cardiorenal outcome benefits seen with sodium-glucose cotransporter 2 inhibitors may partially derive from their interference of some of these same pathways. We also note that many other complications common in diabetes (e.g., hepatic, joint disease, perhaps mental health) are also variably linked to excess adiposity, the aggregated exposure to which has now increased in type 2 diabetes. All such observations suggest a greater need to tackle excess adiposity earlier in type 2 diabetes.
引用
- Sattar N, Presslie C, Rutter MK, et al. Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity. Diabetes Care. 2024. PMID: 38412040. doi:10.2337/dci23-0041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。